ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

Yu Chen, Ping Chi, Shira Rockowitz, Phillip J. Iaquinta, Tambudzai Shamu, Shipra Shukla, Dong Gao, Inna Sirota, Brett S. Carver, John Wongvipat, Howard I. Scher, Deyou Zheng, Charles L. Sawyers

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Studies of ETS-mediated prostate oncogenesis have been hampered by a lack of suitable experimental systems. Here we describe a new conditional mouse model that shows robust, homogenous ERG expression throughout the prostate. When combined with homozygous Pten loss, the mice developed accelerated, highly penetrant invasive prostate cancer. In mouse prostate tissue, ERG markedly increased androgen receptor (AR) binding. Robust ERG-mediated transcriptional changes, observed only in the setting of Pten loss, included the restoration of AR transcriptional output and upregulation of genes involved in cell death, migration, inflammation and angiogenesis. Similarly, ETS variant 1 (ETV1) positively regulated the AR cistrome and transcriptional output in ETV1-translocated, PTEN-deficient human prostate cancer cells. In two large clinical cohorts, expression of ERG and ETV1 correlated with higher AR transcriptional output in PTEN-deficient prostate cancer specimens. We propose that ETS factors cause prostate-specific transformation by altering the AR cistrome, priming the prostate epithelium to respond to aberrant upstream signals such as PTEN loss.

Original languageEnglish (US)
Pages (from-to)1023-1029
Number of pages7
JournalNature Medicine
Volume19
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Androgen Receptors
Prostate
Carcinogenesis
Prostatic Neoplasms
Cell death
Restoration
Cell Movement
Cell Death
Up-Regulation
Epithelium
Genes
Cells
Tissue
Inflammation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Chen, Y., Chi, P., Rockowitz, S., Iaquinta, P. J., Shamu, T., Shukla, S., ... Sawyers, C. L. (2013). ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine, 19(8), 1023-1029. https://doi.org/10.1038/nm.3216

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. / Chen, Yu; Chi, Ping; Rockowitz, Shira; Iaquinta, Phillip J.; Shamu, Tambudzai; Shukla, Shipra; Gao, Dong; Sirota, Inna; Carver, Brett S.; Wongvipat, John; Scher, Howard I.; Zheng, Deyou; Sawyers, Charles L.

In: Nature Medicine, Vol. 19, No. 8, 08.2013, p. 1023-1029.

Research output: Contribution to journalArticle

Chen, Y, Chi, P, Rockowitz, S, Iaquinta, PJ, Shamu, T, Shukla, S, Gao, D, Sirota, I, Carver, BS, Wongvipat, J, Scher, HI, Zheng, D & Sawyers, CL 2013, 'ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss', Nature Medicine, vol. 19, no. 8, pp. 1023-1029. https://doi.org/10.1038/nm.3216
Chen, Yu ; Chi, Ping ; Rockowitz, Shira ; Iaquinta, Phillip J. ; Shamu, Tambudzai ; Shukla, Shipra ; Gao, Dong ; Sirota, Inna ; Carver, Brett S. ; Wongvipat, John ; Scher, Howard I. ; Zheng, Deyou ; Sawyers, Charles L. / ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. In: Nature Medicine. 2013 ; Vol. 19, No. 8. pp. 1023-1029.
@article{e59d55fff16645b28154de1ac795920f,
title = "ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss",
abstract = "Studies of ETS-mediated prostate oncogenesis have been hampered by a lack of suitable experimental systems. Here we describe a new conditional mouse model that shows robust, homogenous ERG expression throughout the prostate. When combined with homozygous Pten loss, the mice developed accelerated, highly penetrant invasive prostate cancer. In mouse prostate tissue, ERG markedly increased androgen receptor (AR) binding. Robust ERG-mediated transcriptional changes, observed only in the setting of Pten loss, included the restoration of AR transcriptional output and upregulation of genes involved in cell death, migration, inflammation and angiogenesis. Similarly, ETS variant 1 (ETV1) positively regulated the AR cistrome and transcriptional output in ETV1-translocated, PTEN-deficient human prostate cancer cells. In two large clinical cohorts, expression of ERG and ETV1 correlated with higher AR transcriptional output in PTEN-deficient prostate cancer specimens. We propose that ETS factors cause prostate-specific transformation by altering the AR cistrome, priming the prostate epithelium to respond to aberrant upstream signals such as PTEN loss.",
author = "Yu Chen and Ping Chi and Shira Rockowitz and Iaquinta, {Phillip J.} and Tambudzai Shamu and Shipra Shukla and Dong Gao and Inna Sirota and Carver, {Brett S.} and John Wongvipat and Scher, {Howard I.} and Deyou Zheng and Sawyers, {Charles L.}",
year = "2013",
month = "8",
doi = "10.1038/nm.3216",
language = "English (US)",
volume = "19",
pages = "1023--1029",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

AU - Chen, Yu

AU - Chi, Ping

AU - Rockowitz, Shira

AU - Iaquinta, Phillip J.

AU - Shamu, Tambudzai

AU - Shukla, Shipra

AU - Gao, Dong

AU - Sirota, Inna

AU - Carver, Brett S.

AU - Wongvipat, John

AU - Scher, Howard I.

AU - Zheng, Deyou

AU - Sawyers, Charles L.

PY - 2013/8

Y1 - 2013/8

N2 - Studies of ETS-mediated prostate oncogenesis have been hampered by a lack of suitable experimental systems. Here we describe a new conditional mouse model that shows robust, homogenous ERG expression throughout the prostate. When combined with homozygous Pten loss, the mice developed accelerated, highly penetrant invasive prostate cancer. In mouse prostate tissue, ERG markedly increased androgen receptor (AR) binding. Robust ERG-mediated transcriptional changes, observed only in the setting of Pten loss, included the restoration of AR transcriptional output and upregulation of genes involved in cell death, migration, inflammation and angiogenesis. Similarly, ETS variant 1 (ETV1) positively regulated the AR cistrome and transcriptional output in ETV1-translocated, PTEN-deficient human prostate cancer cells. In two large clinical cohorts, expression of ERG and ETV1 correlated with higher AR transcriptional output in PTEN-deficient prostate cancer specimens. We propose that ETS factors cause prostate-specific transformation by altering the AR cistrome, priming the prostate epithelium to respond to aberrant upstream signals such as PTEN loss.

AB - Studies of ETS-mediated prostate oncogenesis have been hampered by a lack of suitable experimental systems. Here we describe a new conditional mouse model that shows robust, homogenous ERG expression throughout the prostate. When combined with homozygous Pten loss, the mice developed accelerated, highly penetrant invasive prostate cancer. In mouse prostate tissue, ERG markedly increased androgen receptor (AR) binding. Robust ERG-mediated transcriptional changes, observed only in the setting of Pten loss, included the restoration of AR transcriptional output and upregulation of genes involved in cell death, migration, inflammation and angiogenesis. Similarly, ETS variant 1 (ETV1) positively regulated the AR cistrome and transcriptional output in ETV1-translocated, PTEN-deficient human prostate cancer cells. In two large clinical cohorts, expression of ERG and ETV1 correlated with higher AR transcriptional output in PTEN-deficient prostate cancer specimens. We propose that ETS factors cause prostate-specific transformation by altering the AR cistrome, priming the prostate epithelium to respond to aberrant upstream signals such as PTEN loss.

UR - http://www.scopus.com/inward/record.url?scp=84882285291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882285291&partnerID=8YFLogxK

U2 - 10.1038/nm.3216

DO - 10.1038/nm.3216

M3 - Article

C2 - 23817021

AN - SCOPUS:84882285291

VL - 19

SP - 1023

EP - 1029

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 8

ER -